Senzar Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Senzar Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-90,720	Closed	-$3.33M	–	35
2016 Q3	$3.33M	Sell	90,720 -53,580	-37%	-$1.54M	0.86%	31
2016 Q2	$3.22M	Sell	144,300 -17,320	-11%	-$431K	0.7%	33
2016 Q1	$3.36M	Buy	161,620 +10,270	+7%	+$253K	0.67%	30
2015 Q4	$4.59M	Buy	151,350 +13,791	+10%	+$418K	0.51%	34
2015 Q3	$3.4M	Buy	137,559 +19,910	+17%	+$594K	0.49%	29
2015 Q2	$3.78M	Sell	117,649 -83,980	-42%	-$3.21M	0.65%	35
2015 Q1	$7.2M	Sell	201,629 -10,170	-5%	-$279K	1.75%	19
2014 Q4	$4.81M	Buy	211,799 +4,359	+2%	+$88.2K	1.41%	27
2014 Q3	$4.03M	Buy	207,440 +115,120	+125%	+$3.25M	1.18%	22
2014 Q2	$3.35M	Buy	92,320 +50,180	+119%	+$1.71M	1.28%	24
2014 Q1	$1.64M	Buy	42,140 +30,170	+252%	+$1.08M	0.87%	17
2013 Q4	$341K	Buy	+11,970	New	+$351K	0.28%	19

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Senzar Asset Management's RIGL Position: Q4 2016 in Review

Senzar Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2016, closing a stake of 90,720 shares — an estimated $3.33M sold.

Senzar Asset Management first reported a position in RIGL in Q4 2013 and held it in 12 quarters. The position peaked at $7.2M in Q1 2015. 107 funds tracked by Wall St. Rank hold RIGL as of Q4 2016.

Senzar Asset Management reported no remaining Rigel Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Senzar Asset Management sold 90,720 Rigel Pharmaceuticals shares in Q4 2016, an estimated $3.33M.
Senzar Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2013 and held it in 12 quarters.
Senzar Asset Management's Rigel Pharmaceuticals position peaked at $7.2M in Q1 2015.
107 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2016.

Based on Senzar Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.